# EDGAR Filing Document

**Accession Number:** 0001815442
**File Stem:** 0001193125-26-281051
**Filing Date:** 2026-6
**Character Count:** 6595
**Document Hash:** 0543b8db3c1ee47a24716a1da247d71e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-281051.hdr.sgml**: 20260624

**ACCESSION NUMBER**: 0001193125-26-281051

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260624

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260624

**DATE AS OF CHANGE**: 20260624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kymera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001815442
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812992166
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39460
- **FILM NUMBER:** 261115930

**BUSINESS ADDRESS:**
- **STREET 1:** 500 NORTH BEACON STREET, 4TH FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 857-285-5314

**MAIL ADDRESS:**
- **STREET 1:** 500 NORTH BEACON STREET, 4TH FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 24, 2026

## KYMERA THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39460** | **81-2992166** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### Kymera Therapeutics, Inc.

#### 500 North Beacon Street, 4th Floor

#### Watertown, Massachusetts 02472

#### (Address of principal executive offices, including zip code)
(857) 285-5300

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trade<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.0001 par value per share | KYMR | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders**  |

---

Kymera Therapeutics, Inc. (the "Company") held its Annual Meeting of Shareholders on June 24, 2026 (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company's Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2026. The final voting results are set forth below.

<u>Proposal 1 – Election of Class III Director Nominees</u> 

The shareholders of the Company elected Bruce Booth, D.Phil., Nello Mainolfi, Ph.D., John Maraganore, Ph.D. and Elena Ridloff, CFA as Class III directors of the Company, each to hold office for a three-year term ending at the annual meeting of shareholders to be held in 2029 and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal. The results of the shareholders' vote with respect to the election of the Class III directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Votes<br>For** | **Votes<br>Withheld** | **Broker<br>Non-Votes** |
|  Bruce Booth, D.Phil. | 71962459 | 5430527 | 1707176 |
|  Nello Mainolfi, Ph.D. | 73411316 | 3981670 | 1707176 |
|  John Maraganore, Ph.D. | 72501958 | 4891028 | 1707176 |
|  Elena Ridloff, CFA | 72453404 | 4939582 | 1707176 |

---

<u>Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers</u>

The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The results of the shareholders' non-binding, advisory vote with respect to such approval were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes**<br> **For** | **Votes**<br> **Against** | **Abstain** | **Broker<br>Non-Votes** |
| 74903687 | 2462732 | 26567 | 1707176 |

---

------

<u>Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm</u>

The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the shareholders' vote with respect to such ratification were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes**<br> **For** | **Votes**<br> **Against** | **Abstain** | **Broker<br>Non-Votes** |
| 79,043,801 | 38,128 | 18,233 | 0 |

---

No other matters were submitted to or voted on by the Company's shareholders at the Annual Meeting.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Kymera Therapeutics, Inc. | Kymera Therapeutics, Inc. |
| Date: June 24, 2026 | By: | /s/ Nello Mainolfi |
|  |  | Nello Mainolfi, Ph.D. |
|  |  | President and Chief Executive Officer |

---